Modality
Small Molecule
MOA
Menini
Target
CFTR
Pathway
Fibrosis
Migraine
Development Pipeline
Preclinical
~Jan 2019
→ ~Apr 2020
Phase 1
~Jul 2020
→ ~Oct 2021
Phase 2
Jan 2022
→ Nov 2030
Phase 2Current
NCT03126029
2,642 pts·Migraine
2022-01→2030-11·Active
NCT06727448
1,768 pts·Migraine
2022-09→2026-10·Active
4,410 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2026-10-197mo awayPh3 Readout· Migraine
2030-11-124.6y awayPh3 Readout· Migraine
Trial Timeline
2022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
P2/3
Active
P2/3
Active
Catalysts
Ph3 Readout
2026-10-19 · 7mo away
Migraine
Ph3 Readout
2030-11-12 · 4.6y away
Migraine
Active|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03126029 | Phase 2/3 | Migraine | Active | 2642 | Safety |
| NCT06727448 | Phase 2/3 | Migraine | Active | 1768 | LiverFat |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Mavutenlimab | Johnson & Johnson | Phase 3 | Cl18.2 | |
| Nidasacituzumab | Eli Lilly | Approved | CFTR | |
| Ivorelsin | Eli Lilly | Approved | JAK1 | |
| Datoglumide | AbbVie | Approved | CFTR | |
| SNY-7254 | Sanofi | Phase 2 | CFTR | |
| SNY-5894 | Sanofi | Approved | CFTR | |
| NVO-2974 | Novo Nordisk | NDA/BLA | PARP | |
| Sovarelsin | BioMarin | Phase 2 | CFTR | |
| Fixatuximab | Legend Biotech | Preclinical | CFTR | |
| Doxasotorasib | Samsung Biologics | Phase 2/3 | CFTR |